drugset / Trial / NCT00464620
Trial of Dasatinib in Advanced Sarcomas
Phase 2
Completed
366 enrolled
Sarcoma Alliance for Research through Collaboration
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Timeline
- Start
- 2007-05
- Primary completion
- 2016-12
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 70 mg | Oral |